[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Barretos Cancer Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":96},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100445291","low-cost-imaging-technology-for-global-prevention-of-cervical-cancer-100445291",false,"NCT05078528","Low-cost Imaging Technology for Global Prevention of Cervical Cancer","Low-cost Mobile Colposcopy and Confocal Imaging for Global Prevention of Cervical Cancer","Inclusion Criteria:\n\n* Women \\>25 years of age;\n* Women undergoing colposcopy due to abnormal cervical screening or follow-up for a history of dysplasia;\n* Women of childbearing potential must have a negative urine or blood pregnancy test;\n* Ability to understand and willingness to provide informed consent by signing specific Informed Consent Document.\n\nExclusion Criteria:\n\n* Women under 25 years of age;\n* Women who have undergone hysterectomy with removal of the cervix;\n* Women with known allergy to proflavine or acriflavine;\n* Women who are pregnant or nursing at the time of enrollment;\n* Incapacitated women or in vulnerable situations or who are not willing to give consent;","FEMALE","25 Years",{"count":19,"type":20},1060,"ESTIMATED","INTERVENTIONAL",[23],"NA","Cervical cancer remains the first or second leading cause of cancer death among women in many low-and middle-income countries. Cervical cancer prevention programs in low-resource settings are hampered by a lack of personnel with appropriate clinical expertise, lack of pathology services, and lack of associated infrastructure. There is an urgent need for appropriate diagnostic tools to enable accurate screening and diagnosis in low-resource settings. The purpose of this study is to develop and validate a low-cost Multimodal Mobile Colposcope (MMC) for global cervical cancer prevention programs. This new device will combine the imaging capabilities of a mobile colposcope with the microscopic imaging capabilities of a fiber-optic confocal imaging probe.",[26],"Cervical Intraepithelial Neoplasia",[28,29,30],"image analysis","cancer prevention","cervical intraepithelial neoplasia","RECRUITING","2025-02-04",{"date":34,"type":35},"2025-02-06","ACTUAL",{"date":37,"type":35},"2021-09-20",{"date":39,"type":20},"2025-12-03",{"name":41,"class":42},"Barretos Cancer Hospital","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100543449","phase-4-clinical-outcome-and-biomarkers-for-predicting-immunological-response-in-patients-treated-with-imiquimod-100543449","NCT06356012","Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated with Imiquimod","Immunophenotyping, Microbiome, Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients with High-grade Cervical Intraepithelial Lesions Treated with Imiquimod","Inclusion Criteria:\n\n* Patients between 25 and 45 years of age (reproductive age);\n* High-risk HPV carriers;\n* Residents less than 300 km from the city of Barretos-São Paulo;\n* With a histological diagnosis of high-grade cervical squamous intraepithelial lesion (CIN 3), obtained through colposcopy-guided biopsy performed at the Barretos Cancer Hospital (HCB);\n* Acceptance of the Informed Consent Form.\n\nExclusion Criteria:\n\n* Suspicion of invasive squamous cell carcinoma or Adenocarcinoma (in situ or invasive) by colposcopy and\u002For cytology;\n* Pregnant or breastfeeding;\n* Immunodeficiency condition;\n* Previous treatment for high-grade cervical squamous intraepithelial lesion;\n* Who have been immunized for HPV;\n* Have used antibiotics in the last 30 days",true,"45 Years",{"count":54,"type":20},96,[56],"PHASE4","The goal of this clinical trial is to identify the immunophenotypic profile of the local immune response, the cervicovaginal microenvironment and the microbiological profile of women with CIN 3 treated with imiquimod. Participants will be divided in 3 groups: CIN 3 who will use 16 doses of imiquimod in the uterine cervix, applied twice a week and will be treated with LEEP procedure; 2) patients with CIN 3 who will undergo standard treatment with LEEP procedure; 3) patients with negative cytology and HPV (human papillomavirus) test. Blood and cervicovaginal lavage collections will be performed at different times, for comparisons between cellular response profiles to imiquimod during treatment and baseline levels in healthy patients.",[59,60,61],"HSIL, High-Grade Squamous Intraepithelial Lesions","Vaginal Microbiome","Biomarkers","2025-02-03",{"date":64,"type":35},"2025-02-05",{"date":66,"type":35},"2024-04-02",{"date":68,"type":20},"2028-12-31",{"name":41,"class":42},1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":70},"100477010","hypofractionated-radiotherapy-in-breast-cancer-patients-with-prosthetic-reconstruction-100477010","NCT05491395","Hypofractionated Radiotherapy in Breast Cancer Patients With Prosthetic Reconstruction","Randomized Phase III Clinical Trial of Hypofractionated Radiotherapy in Breast Cancer Patients With Immediate Prosthetic Reconstruction: PROMART Trial","PROMART","Inclusion Criteria:\n\n* Women with confirmed histological diagnosis of invasive ductal carcinoma and lobular breast carcinoma;\n* Radical mastectomy with immediate reconstruction with a prosthesis;\n* Patients indicated for adjuvant RT;\n* Any lymph node status;\n* With or without adjuvant chemotherapy;\n* ECOG performance status from 0-2;\n* \\> 18 years old;\n* Informed Consent Form applied before any study-specific procedure.\n\nExclusion Criteria:\n\n* Another histological diagnosis than invasive ductal carcinoma or lobular carcinoma;\n* Previous history of neoplasm and\u002For radiotherapy and\u002F or quimiotherapy before this study;\n* Distant metastatic disease;\n* Palliative treatment;\n* Patients with scleroderma \u002F systemic lupus erythematosus.","18 Years",{"count":81,"type":20},120,[23],"RATIONALE:\n\nRadiotherapy (RT) can be indicated to patients submitted to breast-conserving surgery, but, despite the benefits, adjuvant RT can cause contracture generated by tissue fibrosis in patients with immediate prosthetic reconstruction, which could cause prosthesis loss. The biological explanation of this outcome is not fully understood, but recent advances in the analysis of patient-derived blood can contribute to establishing a connection of molecular alterations related to this clinical outcome.\n\nThere is not a consensus about using hypofractionated RT schemes for patients with BCS and breast reconstruction since no studies had investigated the reasons why some patients lose the prosthesis.\n\nPURPOSE: This study will evaluate G3 toxicity rate in breast cancer patients with immediate prosthetic reconstruction, submitted to hypofractionated radiotherapy, analyzing capsular contracture, leakage, infection, and bad positioning in order to demonstrate the noninferiority of Hypo-RT with the conventional RT. Additionally, the molecular profile of blood samples will be investigated in order to find biomarkers related to inflammations processes and response to treatment.",[85],"Breast Cancer",[87],"breast cancer, radiation therapy, hypofractionated, biomarkers","2022-08-04",{"date":90,"type":35},"2022-08-08",{"date":92,"type":35},"2022-06-27",{"date":94,"type":20},"2029-05-01",{"name":41,"class":42},""]